5 results about "Myelitis" patented technology

The present invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating symptoms of demyelinating disorders in human or animal subjects in need thereof, the disorders being selected from: enterotoxemia (ET), multiple sclerosis (MS), clinically confirmed MS (CDMS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorders (NMOSD), optic neuritis (ON), neuromyelitis optica (NMO), myelitis, myelitis, transverse myelitis (TM), diseases or disorders characterized by increased or presence of antibodies to aquaporin-4 (AQP-4) and / or astrocyte damage, and acute disseminated encephalomyelitis (ADEM). The method comprises administering to the subject a composition comprising an effective amount of an agent that directly or indirectly interferes with an epsilon toxin (Etx) produced by a type B or D strain of Clostridium perfringens, an Etx-binding receptor, or the interaction of Etx with its binding receptor, thereby inhibiting or suppressing the receptor signaling activity regulated by Etx. The present invention also provides novel polypeptides useful as vaccines against diseases caused by or associated with the epsilon toxin of Clostridium perfringens.

This invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating the symptoms of a demyelinating condition selected from: enterotoxemia (ET), multiple sclerosis (MS), clinically definite MS (CDMS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorder (NMOSD), optic neuritis (ON), neuromyelitis optica (NMO), myelitis, myelitis, transverse myelitis (TM), a disease or condition characterised by the increase or presence of antibodies against aquaporin-4 (AQP-4) and / or astrocyte damage, and acute disseminated encephalomyelitis (ADEM) in a human or animal subject in need. The methods comprise administering to the subject a composition comprising an effective amount of an agent that directly or indirectly interferes with epsilon toxin (ETX) produced by Clostridium perfringens type B or type D bacterial strain, an ETX-binding receptor, or an interaction of ETX with its binding receptor so as to inhibit or suppress ETX modulated receptor signalling activities. The invention also provides novel polypeptides useful as a vaccine against diseases caused by or associated with the epsilon toxin of Clostridium perfringens.

This utility model discloses an electrostimulation therapy helmet with rehabilitation functions, belonging to the field of rehabilitation assistive device technology. It includes a front shell and a rear shell, which are connected together by a head circumference adjuster to form a helmet body adapted to the human head. A strap extending towards the top of the head is provided on the helmet body, and the strap is equipped with a tension adjuster and a head cover. Electrode plates are provided on the inner surfaces of both the rear shell and the head cover, and the inner surfaces of the electrode plates are designed to contact the human head. Specifically, the electrode plates on the inner surface of the rear shell correspond to the balance zone of the human head, and the electrode plates on the inner surface of the head cover correspond to the motor zone of the human head. This utility model provides electrostimulation therapy to the balance and motor zones for people recovering from spinal cord injuries, myelitis, or strokes, helping patients obtain effective rehabilitation stimulation in a home environment and accelerating the rehabilitation process.

The present invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating symptoms of a demyelination disorder in a human or animal subject in need thereof, the present invention relates to a method for treating a disease or condition selected from the group consisting of enterotoxemia (ET), multiple sclerosis (MS), clinically definite MS (CDMS), clinically isolated syndrome (CIS), neuromyelitis optica lineage disease (NMOSD), neuromyelitis (ON), neuromyelitis optica (NMO), myelitis, myelitis, transverse myelitis (TM), a disease or condition characterized by an increase or presence of an antibody to aquaporin-4 (AQP-4) and / or astrocyte damage, and acute disseminated encephalomyelitis (ADEM). The method comprises administering to a subject a composition comprising an effective amount of an agent that directly or indirectly interferes with epsilon toxin (Etx) produced by a Clostridium perfringens type B or type D strain, Etx binding receptor, or interaction of Etx with its binding receptor, to inhibit or repress Etx modulated receptor signaling activity.

The application discloses a cerebrospinal fluid low-abundance protein biomarker for opticospinal myelitis diagnosis and application thereof, and belongs to the field of biomedical technology. The application identifies and screens protein markers capable of having significant difference between NMO patients and healthy people through proteomics technology, and verifies the markers, thereby further improving the accuracy and reliability of diagnosis. Finally, the RAPGEF2 protein which can be used as a biomarker is screened, thereby providing a simple and effective clinical diagnosis means, and NMO patients can be accurately identified in an early stage, and doctors can make more accurate diagnosis and treatment decisions in clinic.